Y-mAbs Therapeutics (YMAB) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

YMAB Y-mAbs Therapeutics

Watchlist

11.235
+0.465+4.32%

Trading Nov 27 10:44 ET

503.21MMarket Cap-20805P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference
GlobeNewswire07:35 ET
Oppenheimer Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $23
Moomoo NewsNov 19 03:36 ET · Ratings
Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock
BenzingaNov 18 09:00 ET
Oppenheimer Initiates Coverage On Y-mAbs Therapeutics With Outperform Rating, Announces Price Target of $23
BenzingaNov 18 08:48 ET · Ratings
Y-mAbs Therapeutics Analyst Ratings
BenzingaNov 15 14:12 ET · Ratings
H.C. Wainwright Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $22
Moomoo NewsNov 15 08:31 ET · Ratings

Comments

Moomoo AI

Mar 24 10:01

Recent insider selling at Y-mAbs Therapeutics may indicate insiders believe shares are overpriced. The absence of insider purchases in the past year and low insider ownership warrant caution.

Selling US$1.9m Of Stock Was Lucrative Decision For Y-mAbs Therapeutics Insiders

Moomoo AI

Mar 3 08:57

The company's cash runway and revenue growth are positive. Its cash burn relative to market capitalisation is low, indicating potential for more cash raising with minimal dilution or borrowing. The company's cash burn is not a concern, suggesting it is well-positioned for continued growth funding.